BioMarin Pharmaceutical has achieved a significant milestone with the U.S. Food and Drug Administration’s approval of Palynziq (pegvaliase-pqpz) for use in adolescents aged 12 and older who suffer from phenylketonuria (PKU). This approval represents a pivotal moment in the treatment landscape for PKU, as Palynziq is now recognized as the sole enzyme substitution therapy capable of effectively reducing blood phenylalanine (Phe) levels for this demographic.
Clinical Trial Success
The FDA’s decision stemmed from compelling evidence gathered through the PEGASUS trial, a Phase III randomized controlled study that evaluated the efficacy and safety of Palynziq in comparison to traditional dietary management alone. This trial specifically focused on adolescents whose blood Phe levels remained uncontrolled, measuring levels exceeding 600µmol/L.
Remarkably, the results revealed that 44.4% of participants achieved Phe levels below recommended guidelines by the end of Part I of the trial. Within this successful cohort, 75% managed to lower their Phe levels to below 120µmol/L. On average, participants experienced a staggering reduction of 828µmol/L, which equates to an impressive 94% decrease from their baseline measurements.
Dietary Impact
The implications of Palynziq on dietary intake were notable as well. Among the nine participants who attained hypophenylalaninaemia, there was a 318.1% increase in intact protein consumption compared to baseline figures, while reliance on medical food protein dropped by 55.16%. In fact, six individuals completely ceased the use of medical food, highlighting the potential for a more flexible diet when using this innovative therapy.
Adverse Reactions and Safety Profile
As with any treatment, it is essential to consider potential side effects. The most frequently reported adverse reactions among adolescents included arthralgia, dizziness, fatigue, hypersensitivity reactions, nausea, pyrexia, and vomiting. Most of these side effects were observed during the initial induction and titration phases of treatment, with a notable decrease during the maintenance phase, suggesting that patients may adapt positively over time.
Commitment to PKU Community
Greg Friberg, BioMarin’s executive vice-president and chief research and development officer, emphasized the company’s longstanding commitment to improving the lives of individuals affected by PKU. With over two decades of collaboration with medical and advocacy groups, BioMarin has introduced several treatment options for this inherited metabolic disorder, which traditionally necessitates strict adherence to a challenging medical diet.
Friberg expressed pride in expanding Palynziq’s indication to include adolescents as young as 12 years old, allowing more patients the opportunity to achieve substantially lower Phe levels. This move not only enhances treatment options but also symbolizes progress in the ongoing fight against PKU.
Looking Ahead: European Expansion
In addition to the U.S. approval, BioMarin is actively pursuing authorization from the European Medicines Agency (EMA) to extend Palynziq’s use to adolescents aged 12 and older across the European Union. This expansion could further amplify the impact of this treatment, potentially reaching a broader patient population in need of effective PKU management strategies.
Future Endeavors
In a related strategic move, BioMarin announced its agreement to acquire Inozyme Pharma for $4.00 per share in a cash transaction valued at $270 million. This acquisition underscores BioMarin’s commitment to broadening its portfolio and enhancing its capabilities within the biotech landscape.
Key Takeaways
- BioMarin has received FDA approval for Palynziq in adolescents aged 12 and above with PKU.
- The PEGASUS trial demonstrated a significant reduction in blood Phe levels, with many participants achieving levels well below guidelines.
-
The treatment allows for increased dietary flexibility, with some patients completely discontinuing medical food.
-
Adverse reactions were manageable and diminished over time, indicating a favorable safety profile.
-
BioMarin is also seeking EMA approval to expand Palynziq’s use in Europe.
In conclusion, the FDA’s approval of Palynziq for adolescents is a promising development in the treatment of PKU, offering new hope for patients and their families. As BioMarin continues to innovate and expand its offerings, the future looks brighter for those navigating the complexities of this metabolic condition.
Read more → www.yahoo.com